SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced that it completed a registered direct offering of 1,743,396 shares of common stock at a price of $8.48 per share, for total gross proceeds of $14.8 million. The closing involved the previously announced sale of 1,443,396 shares of Optimer’s common stock as well as an additional 300,000 shares of Optimer’s common stock which another institutional investor subsequently committed to purchase.
